Literature DB >> 19595460

Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity.

Natalie A Bowerman1, Terence S Crofts, Lukasz Chlewicki, Priscilla Do, Brian M Baker, K Christopher Garcia, David M Kranz.   

Abstract

The potency of a T cell is determined in large part by two interactions, binding of a cognate peptide to the MHC, and binding of the T cell receptor (TCR) to this pepMHC. Various studies have attempted to assess the relative importance of these interactions, and to correlate the corresponding binding parameters with the level of T cell activity mediated by the peptide. To further examine the properties that govern optimal T cell activity, here we engineered both the peptide:MHC interaction and the TCR:pepMHC interaction to generate improved T cell activity. Using a system involving the 2C TCR and its allogeneic pepMHC ligand, QL9-L(d), we show that a peptide substitution of QL9 (F5R), increased the affinity and stability of the pep-L(d) complex (e.g. cell surface t(1/2)-values of 13 min for QL9-L(d) versus 87 min for F5R-L(d)). However, activity of peptide F5R for 2C T cells was not enhanced because the 2C TCR bound with very low affinity to F5R-L(d) compared to QL9-L(d) (K(D)=300 microM and K(D)=1.6 microM, respectively). To improve the affinity, yeast display of the 2C TCR was used to engineer two mutant TCRs that exhibited higher affinity for F5R-L(d) (K(D)=1.2 and 6.3 microM). T cells that expressed these higher affinity TCRs were stimulated by F5R-L(d) in the absence of CD8, and the highest affinity TCR exhibited enhanced activity for F5R compared to QL9. The results provide a guide to designing the explicit binding parameters that govern optimal T cell activities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595460      PMCID: PMC2773466          DOI: 10.1016/j.molimm.2009.06.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  37 in total

1.  Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation.

Authors:  Judith Racape; Francine Connan; Johan Hoebeke; Jeannine Choppin; Jean-Gérard Guillet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

4.  Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes.

Authors:  Nathan J Felix; David L Donermeyer; Stephen Horvath; James J Walters; Michael L Gross; Anish Suri; Paul M Allen
Journal:  Nat Immunol       Date:  2007-02-25       Impact factor: 25.606

Review 5.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

6.  How a single T cell receptor recognizes both self and foreign MHC.

Authors:  Leremy A Colf; Alexander J Bankovich; Nicole A Hanick; Natalie A Bowerman; Lindsay L Jones; David M Kranz; K Christopher Garcia
Journal:  Cell       Date:  2007-04-06       Impact factor: 41.582

7.  Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.

Authors:  Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

8.  Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2.

Authors:  Cheryl E Myers; Sara O Dionne; Kishore Shakalya; Daruka Mahadevan; Margaret H Smith; Douglas F Lake
Journal:  Hum Immunol       Date:  2007-12-31       Impact factor: 2.850

9.  Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide.

Authors:  Amy Gardiner; Katherine A Richards; Andrea J Sant; Lynne S Arneson
Journal:  Int Immunol       Date:  2007-09       Impact factor: 4.823

10.  Structural and kinetic basis for heightened immunogenicity of T cell vaccines.

Authors:  Ji-Li Chen; Guillaume Stewart-Jones; Giovanna Bossi; Nikolai M Lissin; Linda Wooldridge; Ed Man Lik Choi; Gerhard Held; P Rod Dunbar; Robert M Esnouf; Malkit Sami; Jonathan M Boulter; Pierre Rizkallah; Christoph Renner; Andrew Sewell; P Anton van der Merwe; Bent K Jakobsen; Gillian Griffiths; E Yvonne Jones; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

View more
  27 in total

1.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system.

Authors:  Samanthi Narayanan; David M Kranz
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

3.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

4.  Peptide-dependent conformational fluctuation determines the stability of the human leukocyte antigen class I complex.

Authors:  Saeko Yanaka; Takamasa Ueno; Yi Shi; Jianxun Qi; George F Gao; Kouhei Tsumoto; Kenji Sugase
Journal:  J Biol Chem       Date:  2014-07-15       Impact factor: 5.157

5.  A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces.

Authors:  Timothy P Riley; Cory M Ayres; Lance M Hellman; Nishant K Singh; Michael Cosiano; Jennifer M Cimons; Michael J Anderson; Kurt H Piepenbrink; Brian G Pierce; Zhiping Weng; Brian M Baker
Journal:  Protein Eng Des Sel       Date:  2016-09-13       Impact factor: 1.650

6.  Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.

Authors:  Sheena N Smith; Daniel Sommermeyer; Kurt H Piepenbrink; Sydney J Blevins; Helga Bernhard; Wolfgang Uckert; Brian M Baker; David M Kranz
Journal:  J Mol Biol       Date:  2013-08-14       Impact factor: 5.469

Review 7.  Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Authors:  Eric R Lutz; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2014-05-02       Impact factor: 11.151

8.  Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.

Authors:  Jennifer D Stone; David H Aggen; Adam S Chervin; Samanthi Narayanan; Thomas M Schmitt; Philip D Greenberg; David M Kranz
Journal:  J Immunol       Date:  2011-03-30       Impact factor: 5.422

9.  Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.

Authors:  Natalie A Bowerman; Leremy A Colf; K Christopher Garcia; David M Kranz
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

Review 10.  Synthetic immunosurveillance systems: nanodevices to monitor physiological events.

Authors:  Yvon L Woappi; Rahul Jangiti; Om V Singh
Journal:  Biosens Bioelectron       Date:  2014-05-10       Impact factor: 10.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.